MISSISSAUGA, ON, June 17, 2021 /CNW/ - Sanofi Canada announced today that a new 300 mg single-dose (single-use) pre-filled pen for DUPIXENT ® (dupilumab injection) is now available in Canada. The ...
* DUPIXENT ® is the only biologic medicine approved by Health Canada to treat moderate-to-severe atopic dermatitis. * Public reimbursement under the Ontario Exceptional Access Program and the New ...
Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent 300 mg pre-filled pen expected to be available third quarter of 2020 ...
TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...
Dupixent is approved in 60 countries for adults with moderate-to-severe atopic dermatitis, one of the diseases driven by type 2 inflammation Atopic dermatitis is a chronic inflammatory disease that ...
July 3 (Reuters) - Sanofi (SASY.PA), opens new tab and partner Regeneron (REGN.O), opens new tab on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a ...
The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
This approval was based on findings from two clinical studies conducted in adult patients already receiving maximal standard-of-care inhaled therapy. The BOREAS and NOTUS studies showed a 30% and 34% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback